Yasuchika Hasegawa, president of Takeda Pharmaceutical Company, had a vision to make Takeda a top tier company in oncology by 2015. In 2008, Takeda obtained Millennium Pharmaceuticals, a revered oncology company with yearly income of $528 million in 2007 and a talented pipeline of innovative drugs. Hasegawa and Millennium CEO Deborah Dunsire alleged that it was essential to communicate a reliable vision for the prospect of Millennium within Takeda and assist Millennium workers feel positive concerning the organization 's future.
Millennium would manage independently and become Takeda's "Center of Excellence in Oncology." This case explores the measures that Hasegawa took to incorporate Millennium. His precedence centered on retaining Millennium ability and addressing the clash that originated from two quite different corporate cultures. He also used the opportunity to transform the risk averse culture of Takeda into a more innovative and flexible one which will support Takeda becoming a really international pharmaceutical company.
Takeda Pharmaceutical Company (B) The Millennium Acquisition case study solution
PUBLICATION DATE: March 06, 2012 PRODUCT #: OB83B-HCB-ENG
This is just an excerpt. This case is about STRATEGY & EXECUTION
Related Case Solutions & Analyses:
Ontela PicDeck (B): Customer Segmentation Targeting and Positioning
Ontela PicDeck (A): Customer Segmentation Targeting and Positioning
Communispace
Hass Shoes
Aetna Inc.: Managing Inherent Enterprise Risks Through Stakeholder Management (A)
Miracle Life Inc.
LG Electronics Canada Inc. – The Watch Phone
Note on Test Marketing
Storm Gudrun: Managing a Crisis
Wheres the Fine Print Advertising and the Mortgage Market Crisis
